Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 18/20 | 0.81 |
| ▸ | L3MBTL1 | Q9Y468 | 16/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | HPGD | P15428 | 1/20 | 0.78 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.59 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.59 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.59 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4157157 | 0.85 | HPGD (0.66) | L3MBTL3L3MBTL1ALDH1A1HPGD | |
| SCHEMBL27688414 | 0.84 | L3MBTL3 (0.88) | L3MBTL3L3MBTL1ALDH1A1HPGDMBTD1 | |
| SCHEMBL277178 | 0.82 | L3MBTL3 (0.79) | L3MBTL3L3MBTL1ALDH1A1HPGDMBTD1 | |
| SCHEMBL12265877 | 0.82 | L3MBTL3 (0.74) | L3MBTL3L3MBTL1ALDH1A1HPGDMBTD1 | |
| SCHEMBL12313389 | 0.82 | L3MBTL3 (0.74) | L3MBTL3L3MBTL1ALDH1A1HPGDMBTD1 | |
| SCHEMBL14395488 | 0.82 | L3MBTL3 (0.78) | L3MBTL3L3MBTL1ALDH1A1HPGDMBTD1 | |
| SCHEMBL17319591 | 0.81 | HPGD (0.66) | L3MBTL3L3MBTL1ALDH1A1HPGD | |
| SCHEMBL12265916 | 0.80 | L3MBTL3 (0.79) | L3MBTL3L3MBTL1ALDH1A1HPGDMBTD1 | |
| SCHEMBL3771922 | 0.79 | ALDH1A1 (0.74) | L3MBTL3L3MBTL1ALDH1A1HPGD | |
| SCHEMBL21230300 | 0.78 | HPGD (0.59) | L3MBTL3L3MBTL1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371416-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-02 | — | — | US | disclosed |
| US-10590129-B2 | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2020-03-17 | — | — | US | disclosed |
| US-20190218211-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20180072721-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED-3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2018-03-15 | — | — | US | disclosed |
| US-9815831-B2 | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2017-11-14 | — | — | US | disclosed |
| US-9815831-B2 | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2017-11-14 | — | — | US | disclosed |
| US-20170240542-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED-3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-20170240542-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED-3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-20150133449-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2015-05-14 | — | — | US | disclosed |
| US-20150133449-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2015-05-14 | — | — | US | disclosed |
| US-8481739-B2 | 3,5-Disubstituted-3H-imidazo[4,5-b]pyridine and 3,5-disubstituted-3H[1,2,3]triazolo [4,5-b] Pyridine Compounds as Modulators of protein kinases | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2013-07-09 | — | — | US | disclosed |
| US-8481739-B2 | 3,5-Disubstituted-3H-imidazo[4,5-b]pyridine and 3,5-disubstituted-3H[1,2,3]triazolo [4,5-b] Pyridine Compounds as Modulators of protein kinases | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2013-07-09 | — | — | US | disclosed |
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| WO-2011145035-A1 | NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | INDIAN INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-11-24 | — | — | WO | disclosed |
| US-20110281865-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2011-11-17 | — | — | US | disclosed |
| US-20110281865-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2011-11-17 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1845090-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281865-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | MAP4K2, MAP4K3, MAP3K1 | L3MBTL3 3572/4885L3MBTL1 3868/4885ALDH1A1 3373/4885 |
| US-20150133449-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | MAP4K2, MAP4K3, MAP3K1 | L3MBTL3 3572/4885L3MBTL1 3868/4885ALDH1A1 3373/4885 |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | L3MBTL3 1219/4885L3MBTL1 676/4885ALDH1A1 2047/4885 |
| US-10590129-B2 | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases | MAP4K2, MAP3K3, MAP3K1 | L3MBTL3 3065/4885L3MBTL1 3638/4885ALDH1A1 3501/4885 |
| US-20180072721-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED-3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES | MET, PRKCH, PRKCE | L3MBTL3 2377/4885L3MBTL1 2796/4885ALDH1A1 3113/4885 |
| US-20190218211-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | MAP4K2, MAP4K3, MAP3K1 | L3MBTL3 3572/4885L3MBTL1 3868/4885ALDH1A1 3373/4885 |
| US-20210371416-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES | MET, PRKCH, PRKCE | L3MBTL3 2377/4885L3MBTL1 2796/4885ALDH1A1 3113/4885 |
| US-20170240542-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED-3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | MAP4K2, MAP4K3, MAP3K1 | L3MBTL3 3572/4885L3MBTL1 3868/4885ALDH1A1 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.